The ADC space has an awkward problem: what happens when your patients stop responding to ADCs? That’s the question CanWell Pharma is trying to answer — and the FDA just gave them the green light to find out. The Woburn, MA-based company received IND clearance for CAN016, a HER2-targeting dual-payload antibody-drug conjugate built on its proprietary StarLinker platform.
Let me say that again: dual-payload. Two distinct cytotoxic payloads conjugated to a single antibody. The design rationale is that single-payload ADCs — your Enhertu, your Padcev, your T-DXd — can develop resistance when tumor cells evolve to evade one mechanism of cell killing. By hitting them with two payloads simultaneously, CAN016 is designed to stay one step ahead of resistance.
And here’s the kicker: the Phase 1 trial isn’t enrolling treatment-naive patients. It’s specifically targeting patients with solid tumors who have already progressed on ADC-based therapies. That’s a post-ADC population — the hardest patients to treat in the current landscape, and a population that barely existed five years ago.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
The timing is interesting when you look at what’s happening across the ADC field. Adcytherix — which we covered today — just dosed its first patient with ADCX-020, exploring novel payload classes to overcome resistance. The entire next wave of ADC development is increasingly defined not by “can we hit the target?” but by “what do we do when the first ADC stops working?” CanWell and Adcytherix are arriving at the same problem from different angles: CanWell with dual payloads on the same antibody, Adcytherix with novel payload chemistries.
CanWell isn’t a one-trick shop either. The company also has CAN1012 in a Phase 1/2 for intratumoral injection in advanced solid tumors and CAN2109 in Phase 1 for solid tumors and lymphoma. But CAN016 and the StarLinker platform are clearly the headline story — it’s a differentiated engineering approach to a problem that’s only going to get bigger as more ADCs reach the market.
Phase 1. Safety and PK as primary endpoints. Early days. But the design philosophy — building for resistance from day one — is exactly where the field needs to go.
